Q-omics provides the consensus-scored SPAG9 profile across patient tissues and cancer cell-line models. SPAG9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SPAG9 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SPAG9 protein abundance shows 22,451 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, HNSC, and LUAD as cancer lineages where SPAG9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPAG9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPAG9 survival associations across molecular data types. SPAG9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPAG9 RNA expression–survival associations across cancer types. High SPAG9 expression shows unfavorable associations in BLCA, ACC, STAD and LUSC, but favorable associations in KIRC and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SPAG9 RNA expression.
This table summarizes SPAG9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SPAG9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPAG9 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, KIRP and CHOL. The HNSC box plot shows higher SPAG9 RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with SPAG9 in patient tissues and cancer cell lines. In patient samples, SPAG9 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPAG9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
